Core Viewpoint - BeiGene's new drug, a BCL2 inhibitor named Baiyueda (sotoclisib), has officially launched in China, marking a significant advancement in treatment options for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), as well as relapsed or refractory mantle cell lymphoma (MCL) [1] Group 1 - BeiGene's stock opened over 3% higher, reaching a price of 210.8 HKD with a trading volume of 16.78 million HKD [1] - The drug Baiyueda has commenced supply in 70 cities across China as of January 13 [1] - Multiple medical institutions nationwide have begun prescribing Baiyueda, allowing it to benefit patients with CLL/SLL and R/R MCL [1] Group 2 - Baiyueda received conditional approval from the National Medical Products Administration (NMPA) on December 30, 2025, based on positive results from clinical studies BGB-11417-201 and BGB-11417-202 [1] - The clinical results demonstrated significant remission benefits in treated CLL/SLL and R/R MCL patients, with good overall tolerability and safety [1]